Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
EBI-ADHD is an evidence-based medicine platform focused on ADHD interventions. It is not positioned as a traditional educational course, but rather as an “Evidence Matrix” of scientific evidence. It aggregates findings from clinical trials and meta-analyses to help clinicians, people with ADHD and their caregivers, researchers, and guideline developers understand the effectiveness and tolerability of different interventions. The platform clearly states that it is not a clinical guideline, but a tool to support informed choices and shared decision-making.
In terms of subject matter, EBI-ADHD focuses on evidence for ADHD treatment and interventions. It covers more than 30 interventions, including 12 categories of medications, 8 types of psychosocial interventions, 3 types of brain stimulation, and 9 lifestyle and other interventions. Its evidence base appears fairly robust: the main text mentions meta-analyses of over 200 trials involving more than 50,000 participants with ADHD. As for delivery format, the website mentions an interactive tutorial, but does not show live classes, recorded courses, one-on-one tutoring, a structured syllabus, or assignments and assessments. As such, it is better suited as a professional knowledge base and learning tool than as a complete course product.
The platform was developed by researchers, with core members including multiple contributors with PhD and MD/PhD backgrounds. It has received public and peer-reviewed research funding from organizations and programs such as France’s Agence Nationale de la Recherche, France 2030, and the UK’s NIHR. The website emphasizes scientific independence and methodological rigor, and notes that its methods and findings have been published in high-impact medical journals. In terms of accreditation, the main text does not mention learning certificates, continuing education credits, or completion certificates. As for pricing, the platform describes itself as freely available to clinicians, researchers, and families worldwide, with no visible subscription fees or payment information.
Its strengths are transparent evidence sources, broad coverage of intervention types, and suitability for clinical shared decision-making. It has also been refined with feedback from more than 100 clinicians and more than 100 people with lived experience across 30 countries, giving it practical relevance. Its limitations are that it is not a structured beginner-oriented course, nor does it replace clinical guidelines or medical diagnosis and treatment. For ordinary parents or patients without a background in medicine or statistics, concepts such as meta-analysis, efficacy, and tolerability metrics may require some effort to understand. The main text also does not indicate whether a Chinese version, customer support, or localized materials are available.
EBI-ADHD is best suited for psychiatrists, pediatricians, mental health professionals, ADHD researchers, guideline developers, and patients or caregivers who want to have informed discussions with their doctors. The main text does not specify access conditions from China, and there is no clear information on network accessibility or payment. Since the platform appears to be free, payment barriers may be relatively low, but language and medical terminology may still be the main challenges. Alternative or supplementary resources may include U-REACH-related platforms, PubMed, Cochrane Library, and authoritative ADHD clinical guidelines.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on ebiadhd-database.org official site.
ebiadhd-database.org is an Unknown Education provider. TG4G tracks its product information, an overall rating of 7.0/10, and a China-accessibility score of Workable. Click "Visit Official Site" to reach ebiadhd-database.org directly.